{"id":64303,"date":"2026-04-30T14:24:43","date_gmt":"2026-04-30T06:24:43","guid":{"rendered":"https:\/\/flcube.com\/?p=64303"},"modified":"2026-04-30T14:24:44","modified_gmt":"2026-04-30T06:24:44","slug":"allist-pharmaceuticals-secures-nmpa-approval-for-pivotal-trial-of-furmonertinib-against-standard-egfr-tkis-in-rare-nsclc-mutations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64303","title":{"rendered":"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations"},"content":{"rendered":"\n<p><strong>Allist Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688578:SHA\">SHA: 688578<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved a <strong>pivotal clinical study<\/strong> comparing its investigational <strong>furmonertinib<\/strong> against <strong>osimertinib or afatinib<\/strong> as <strong>first-line treatment<\/strong> for patients with <strong>locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong> harboring rare <strong>epidermal growth factor receptor (EGFR) P-loop and alpha-C helix compression (PACC) mutations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization for pivotal comparative study<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Head-to-head comparison: furmonertinib vs. osimertinib\/afatinib<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line treatment of EGFR PACC-mutant NSCLC<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Locally advanced or metastatic NSCLC with rare EGFR PACC mutations<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase III-ready based on robust Phase Ib data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Furmonertinib<\/strong>: <strong>Irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor<\/strong> discovered in-house by Allist<\/li>\n\n\n\n<li><strong>Target Specificity<\/strong>: Designed to address rare <strong>EGFR PACC mutations<\/strong> that may not respond optimally to current standard EGFR TKIs<\/li>\n\n\n\n<li><strong>Development Partnership<\/strong>: Co-developed outside Greater China with <strong>ArriVent Biopharma<\/strong> under 2021 strategic agreement<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral therapy with demonstrated central nervous system penetration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-data-further-phase-ib-study\">Clinical Data \u2013 FURTHER Phase Ib Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (240 mg dose group)<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Design<\/strong><\/td><td>Global, randomized, multicenter, multi-cohort Phase Ib<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced NSCLC with EGFR PACC mutations (first-line)<\/td><\/tr><tr><td><strong>Confirmed ORR (BICR-assessed)<\/strong><\/td><td>68.2%<\/td><\/tr><tr><td><strong>Mutation Coverage<\/strong><\/td><td>Effective across both single and compound PACC mutations<\/td><\/tr><tr><td><strong>Median Duration of Response (DoR)<\/strong><\/td><td>14.6 months<\/td><\/tr><tr><td><strong>Median Progression-Free Survival (mPFS)<\/strong><\/td><td>16.0 months<\/td><\/tr><tr><td><strong>Brain Metastases Activity<\/strong><\/td><td>Favorable anti-tumor activity demonstrated<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>No new safety signals identified; favorable tolerability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-unmet-need\">Market Context &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Population Rarity<\/strong><\/td><td>EGFR PACC mutations represent a small but clinically significant subset of NSCLC patients with limited optimal treatment options<\/td><\/tr><tr><td><strong>Current Standard Limitations<\/strong><\/td><td>Osimertinib and afatinib may have suboptimal efficacy in PACC-mutant populations despite broad EGFR inhibition<\/td><\/tr><tr><td><strong>Diagnostic Infrastructure<\/strong><\/td><td>Growing availability of comprehensive genomic profiling in China enables identification of rare mutation carriers<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Potential to establish first mutation-specific standard of care for this molecularly-defined patient subset<\/td><\/tr><tr><td><strong>Global Relevance<\/strong><\/td><td>Addresses unmet need across all markets where EGFR-mutant NSCLC is diagnosed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-commercial-outlook\">Strategic Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Medicine Leadership<\/strong>: Positions Allist at forefront of mutation-specific NSCLC therapeutics in China<\/li>\n\n\n\n<li><strong>Global Commercial Potential<\/strong>: Strong Phase Ib data supports international regulatory strategy through ArriVent partnership<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong>: Mutation-specific efficacy could command premium pricing and preferred positioning in treatment guidelines<\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: Success validates Allist&#8217;s target discovery capabilities and structure-based drug design platform<\/li>\n\n\n\n<li><strong>Competitive Moat<\/strong>: First-mover advantage in addressing PACC mutations creates significant barrier to entry for competitors<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory outcomes, and commercial potential for furmonertinib. Actual results may differ due to risks including pivotal trial outcomes, competitive developments, and evolving regulatory requirements for targeted oncology therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688578_20260430_3VOZ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688578_20260430_3VOZ.\"><\/object><a id=\"wp-block-file--media-3391567f-0221-4fdb-9f64-ce780fcd7fad\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688578_20260430_3VOZ.pdf\">688578_20260430_3VOZ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688578_20260430_3VOZ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3391567f-0221-4fdb-9f64-ce780fcd7fad\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China&#8217;s National Medical Products Administration (NMPA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[138,922],"class_list":["post-64303","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-allist-pharmaceuticals","tag-sha-688578"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China&#039;s National Medical Products Administration (NMPA) has approved a pivotal clinical study comparing its investigational furmonertinib against osimertinib or afatinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring rare epidermal growth factor receptor (EGFR) P-loop and alpha-C helix compression (PACC) mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64303\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations\" \/>\n<meta property=\"og:description\" content=\"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China&#039;s National Medical Products Administration (NMPA) has approved a pivotal clinical study comparing its investigational furmonertinib against osimertinib or afatinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring rare epidermal growth factor receptor (EGFR) P-loop and alpha-C helix compression (PACC) mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64303\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T06:24:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T06:24:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64303#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64303\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations\",\"datePublished\":\"2026-04-30T06:24:43+00:00\",\"dateModified\":\"2026-04-30T06:24:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64303\"},\"wordCount\":467,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Allist Pharmaceuticals\",\"SHA: 688578\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64303#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64303\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64303\",\"name\":\"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-30T06:24:43+00:00\",\"dateModified\":\"2026-04-30T06:24:44+00:00\",\"description\":\"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's National Medical Products Administration (NMPA) has approved a pivotal clinical study comparing its investigational furmonertinib against osimertinib or afatinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring rare epidermal growth factor receptor (EGFR) P-loop and alpha-C helix compression (PACC) mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64303#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64303\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64303#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations - Insight, China&#039;s Pharmaceutical Industry","description":"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's National Medical Products Administration (NMPA) has approved a pivotal clinical study comparing its investigational furmonertinib against osimertinib or afatinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring rare epidermal growth factor receptor (EGFR) P-loop and alpha-C helix compression (PACC) mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64303","og_locale":"en_US","og_type":"article","og_title":"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations","og_description":"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's National Medical Products Administration (NMPA) has approved a pivotal clinical study comparing its investigational furmonertinib against osimertinib or afatinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring rare epidermal growth factor receptor (EGFR) P-loop and alpha-C helix compression (PACC) mutations.","og_url":"https:\/\/flcube.com\/?p=64303","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T06:24:43+00:00","article_modified_time":"2026-04-30T06:24:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64303#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64303"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations","datePublished":"2026-04-30T06:24:43+00:00","dateModified":"2026-04-30T06:24:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64303"},"wordCount":467,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Allist Pharmaceuticals","SHA: 688578"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64303#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64303","url":"https:\/\/flcube.com\/?p=64303","name":"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-30T06:24:43+00:00","dateModified":"2026-04-30T06:24:44+00:00","description":"Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China's National Medical Products Administration (NMPA) has approved a pivotal clinical study comparing its investigational furmonertinib against osimertinib or afatinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring rare epidermal growth factor receptor (EGFR) P-loop and alpha-C helix compression (PACC) mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64303#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64303"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64303#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64303"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64303\/revisions"}],"predecessor-version":[{"id":64307,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64303\/revisions\/64307"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}